Search

Johnson and Johnson

Closed

SectorHealthcare

265.58 -0.28

Overview

Share price change

24h

Current

Min

265.7

Max

270.19

Key metrics

By Trading Economics

Income

299M

5.5B

Sales

1.2B

25B

P/E

Sector Avg

31.966

56.597

EPS

2.9

Dividend yield

1.88

Profit margin

21.865

Employees

138,200

EBITDA

721M

9B

Dividends

By Acuity

Dividend yield

Sector Avg

1.88%

2.18%

Next Earnings

13 paź 2026

Next Dividend date

8 gru 2026

Next Ex Dividend date

24 lis 2026

Market Stats

By TradingEconomics

Market Cap

45B

663B

Previous open

265.86

Previous close

265.58

News Sentiment

By Acuity

49%

51%

142 / 339 Ranking in Healthcare

Johnson and Johnson Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 wrz 2026, 20:07 UTC

Social Media
News

Johnson & Johnson shares are lower despite receiving CE Marking for its ACUVUE OASYS MAX 2-Week lens, with HSBC raising its price target to $320.

9 wrz 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

8 wrz 2026, 20:02 UTC

Social Media

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

5 wrz 2026, 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

4 wrz 2026, 20:08 UTC

News

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

3 wrz 2026, 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2 wrz 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

1 wrz 2026, 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

31 sie 2026, 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

29 sie 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28 sie 2026, 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27 sie 2026, 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26 sie 2026, 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25 sie 2026, 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24 sie 2026, 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21 sie 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20 sie 2026, 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

19 sie 2026, 19:32 UTC

News
Social Media

Johnson & Johnson shares advance as EVP Jennifer Taubert exercises options for 15,000 shares valued at $2.38 million and receives regulatory clearance for MONARCH QUEST 3 software.

18 sie 2026, 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

17 sie 2026, 23:06 UTC

Johnson & Johnson's shares are roughly flat in after-market trading. The stock remains positioned above its 20-day moving average and near its one-month range.

14 sie 2026, 19:46 UTC

Johnson & Johnson shares are lower as pharmaceuticals sub-sector weakness persists. The stock reached a session low earlier before recovering slightly.

13 sie 2026, 19:21 UTC

Johnson & Johnson shares are higher, reflecting broader market gains amid stabilizing inflation pressures and a drop in crude oil prices.

12 sie 2026, 23:26 UTC

Johnson & Johnson shares are lower in after-market trading, despite initially rising above Wednesday's close. The stock remains above its 20-day moving average.

11 sie 2026, 19:26 UTC

Johnson & Johnson shares are lower today, influenced by a downturn in the Pharmaceuticals sub-sector. The stock has shown notable volatility during the session.

10 sie 2026, 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

8 sie 2026, 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7 sie 2026, 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6 sie 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

5 sie 2026, 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

4 sie 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

Peer Comparison

Price change

Johnson and Johnson Forecast

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Sentiment

By Acuity

142 / 339 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat